Lessons and future directions for GBA1-targeting therapies
- PMID: 37479362
- DOI: 10.1016/S1474-4422(23)00217-X
Lessons and future directions for GBA1-targeting therapies
Conflict of interest statement
I have consulted for Bial, Bial Biotech, Capsida Biotherapeutics, Handl Therapeutics, Idorsia, Neuron23, Ono Pharmaceutical, Prevail Therapeutics, UCB, and Vanqua Bio.
Comment on
-
Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.Lancet Neurol. 2023 Aug;22(8):661-671. doi: 10.1016/S1474-4422(23)00205-3. Lancet Neurol. 2023. PMID: 37479372 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical